Marpai (MRAI) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Revenue declined 28% year-over-year to $7.2 million for Q2 2024, primarily due to customer turnover and market evolution.
Net loss widened to $13.0 million in Q2 2024, up 72% from Q2 2023, driven by a $7.6 million impairment charge.
Leadership is focused on a turnaround with profitable growth, positive cash flow, and operational improvements.
Management is reviewing strategic alternatives, including investment, merger, or sale, to maximize shareholder value.
Company transitioned its stock listing from Nasdaq to OTCQX in May 2024.
Financial highlights
Q2 2024 revenue was $7.2 million, down from $10.0 million in Q2 2023; six-month revenue was $14.6 million, down from $19.7 million.
Operating loss for Q2 2024 was $12.3 million, up from $7.3 million in Q2 2023.
Cash operating expenses were reduced by 38%, saving approximately $4 million.
Net cash increased by $600,000 in Q2 2024, compared to a $2.3 million decrease in Q2 2023.
Cash and cash equivalents at June 30, 2024, were $1.3 million, with restricted cash of $12.8 million and negative working capital of $1.5 million.
Outlook and guidance
Leadership remains optimistic about achieving positive cash flow and continued growth, with a focus on operational improvements and cost-saving initiatives.
Management is seeking additional capital through equity or debt to fund operations and investment needs.
Substantial doubt exists about the company's ability to continue as a going concern over the next 12 months.
Strategic alternatives under review may include investment, merger, or sale.
Management expects to highlight the Q1 2025 sales pipeline after the third quarter.
Latest events from Marpai
- Q2 2026 revenue fell 10.5% to $4.2M, with a $4.6M net loss and ongoing liquidity concerns.MRAI
Q2 2026 - Q1 2026 saw revenue drop 18% and a net loss of $3.2M, with urgent liquidity and debt restructuring.MRAI
Q1 2026 - Revenue declined 36% and net loss improved, but liquidity and going concern risks remain acute.MRAI
Q4 2025 - Board seeks approval for director elections, auditor ratification, and preferred stock authorization.MRAI
Proxy Filing - Shareholders will vote on director elections, auditor ratification, and preferred stock authorization.MRAI
Proxy Filing - Facing ongoing losses and liquidity risks, the company relies on new capital to sustain operations.MRAI
Registration Filing - Q2 2025 saw revenue drop but major cost cuts, with profitability targeted for early 2026.MRAI
Q2 2025 - Q3 2024 losses narrowed as cost cuts and investments offset revenue decline and liquidity risks.MRAI
Q3 2024 - Losses narrowed in 2024; new PBM products and partnerships target 2025 profitability.MRAI
Q4 2024